GlassScriptPhysician profile
Amanda L Brock
NPI 1063121689
$2,583.38
in general payments reported to CMS, 2019-2025
21 companies · $1,024 in 2025
The $1,024 reported for 2025 was more than what 87% of Primary Care providers received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $520 · 2024: $1,039 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,583.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $450.08 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $429.12 | 2023-2025 | Jardiance, Mounjaro, Emgality |
| Abbvie INC. | $360.64 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $232.77 | 2024-2025 | Ofev, Jascayd, Jardiance |
| Edwards Lifesciences Corporation | $166.79 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Pfizer INC. | $146.31 | 2023-2025 | |
| Dexcom, INC. | $139.46 | 2023-2024 | Dexcom G6 Transmitter |
| Amgen INC. | $129.67 | 2023-2025 | Repatha, Otezla, Repatha |
| Novo Nordisk INC | $88.47 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $76.39 | 2023-2025 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $72.86 | 2025 | |
| Glaxosmithkline, LLC. | $61.56 | 2023-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Philips North America LLC | $52.26 | 2024-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided |
| Otsuka America Pharmaceutical, INC. | $42.36 | 2023-2024 | Rexulti |
| Corium, LLC | $36.15 | 2023 | Azstarys |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $19.38 | 2024 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.30 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $16.58 | 2025 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $16.20 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $15.68 | 2024 | Evkeeza |
| Boston Scientific Corporation | $13.35 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Brock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.